Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated in adults for the treatment of BRAF V600 positive unresectable or metastatic melanoma.1,2
Landmark data demonstrate Tafinlar + Mekinist achieves durable overall survival and long-term progression-free survival benefits versus BRAF inhibitor alone that are maintained over 5 years. Treatment with Tafinlar + Mekinist is also associated with an established safety profile.3
Please select an option below to find out more about patient management, or the efficacy and safety profile of Tafinlar + Mekinist for the treatment of BRAF-positive metastatic melanoma.
- Tafinlar (dabrafenib) Summary of Product Characteristics.
- Mekinist (trametinib) Summary of Product Characteristics.
- Robert C et al. N Engl J Med. 2019 Aug 15; 381:626–636.